Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.

Zylberberg H, Pialoux G, Carnot F, Landau A, Bréchot C, Pol S.

Clin Infect Dis. 1998 Nov;27(5):1255-8.

2.

Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.

Karras A, Rabian C, Zylberberg H, Hermine O, Duchatelle V, Durand F, Valla D, Viard JP.

AIDS. 1998 May 7;12(7):827-9. No abstract available.

PMID:
9619823
3.

Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.

Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA.

Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):597-602. Epub 2001 Jan 2.

4.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646
5.

Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.

Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U.

AIDS. 1998 May 7;12(7):829-30. No abstract available.

PMID:
9619824
6.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
8.

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects.

Zylberberg H, Chaix ML, Rabian C, Rouzioux C, Aulong B, Bréchot C, Viard JP, Pol S.

Clin Infect Dis. 1998 May;26(5):1104-6.

9.

Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.

Yamamoto Y, Yasuoka A, Tachikawa N, Teruya K, Genka I, Yamaguchi M, Yasuoka C, Kikuchi Y, Aoki M, Oka S.

Jpn J Infect Dis. 1999 Dec;52(6):248-9. No abstract available.

PMID:
10738365
10.

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH.

J Infect Dis. 1998 Mar;177(3):783-5.

11.

Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.

Thuret I, Michel G, Chambost H, Tamalet C, Giraud P, Brunet C, Perrimond H.

AIDS. 1999 Jan 14;13(1):81-7.

PMID:
10207548
12.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
13.

Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.

Villalba N, Gómez-Cano M, Casas E, Soriano V, Valencia E, González-Lahoz J.

AIDS. 1997 Dec;11(15):1896-7. No abstract available.

PMID:
9412717
14.

Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.

Matsiota-Bernard P, Vrioni G, Onody C, Bernard L, de Truchis P, Peronne C.

Int J Antimicrob Agents. 2001 Feb;17(2):155-7.

PMID:
11165122
15.

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T; MultivirC Group.

Hepatology. 2001 Aug;34(2):283-7.

PMID:
11481613
16.

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].

Gavazzi G, Richallet G, Morand P, Bouchard O, Bosseray A, Leclercq P, Micoud M.

Pathol Biol (Paris). 1998 Jun;46(6):412-5. French.

PMID:
9769871
17.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E.

AIDS. 2001 Jan 5;15(1):F1-9.

PMID:
11192874
19.

Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.

Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ; AIDS Clinical Trials Group 320 Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):426-33. Epub 2004 Jul 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk